Skip to main content
Go to homepage

Omaveloxolone for patients with mitochondrial myopathy

Omaveloxolone (RTA 408) for patients with mitochondrial myopathy

Description:

This study is closed.

For more information on this study, visit: https://clinicaltrials.gov/ct2/show/NCT02255422

Who May Qualify?:

Male or female mitochondrial myopathy patients 18 through 75 years of age.

We will screen potential study participants for additional criteria.

Who Does Not Qualify:

For detailed information on qualifying for enrollment visit: https://clinicaltrials.gov/ct2/show/NCT02255422

Study Status:
Closed
Study Sponsor:

Reata Pharmaceuticals, Inc.

Full IRB Study Title:
A Phase 2 Study of the Safety, Efficacy and Pharmacodynamics of RTA 408 in the Treatment of Mitochondrial Myopathy
IRB Study ID:
408-C-1403
If you are interested in this study or have questions about your child's eligibility, please contact:

Rebecca D. Considine Research Institute, 330-543-5012

Lead Investigator
Bruce H. Cohen, MD, FAAN

Director, NeuroDevelopmental Science Center; Interim Vice President and Medical Director, Rebecca D. Considine Research Institute; Pediatric Neurologist
Pediatric Brain Tumor ProgramPediatric Neurology